References
- Bateman-House, A., and C.T. Robertson. 2018. The federal right to try act of 2017-a wrong turn for access to investigational drugs and the path forward. JAMA Internal Medicine 178(3): 321–2.
- Blumenthal-Barby, J.S., and P.A. Ubel. 2018. In defense of “denial”: Difficulty knowing when beliefs are unrealistic and whether unrealistic beliefs are bad. American Journal of Bioethics 18(9): 4–15.
- Califf, R.M. 2016. Memorandum Re Scientific Dispute Regarding Accelerated Approval of Sarepta Therapeutics’ Eteplirsen (NDA 206488) – Commissioner’s Decision. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_summary%20review_Redacted.pdf.
- Carrieri, D., F.A. Peccatori, and G. Boniolo. 2018. The ethical plausibility of the 'Right To Try' laws. Critical Reviews in Oncology/Hematology 122: 64–71.
- Feudtner, C. 2009. The breadth of hopes. The New England Journal of Medicine 361(24): 2306–2307.
- Goldwater Institute 2018. “Why We Need Right To Try.” Available at: http://righttotry.org/about-right-to-try/.
- Mayer, M. 2003. From access to evidence: An advocate’s journey. Journal of Clinical Oncology 21(20): 3881–3884.
- Murdoch, C.J., and C.T. Scott. 2010. Stem cell tourism and the power of hope. American Journal of Bioethics 10(5): W1–W21.
- Pulliam, S., and B. Mullins. 2017. Hidden influence: How the FDA approved a $300,000-a-year drug its own experts didn’t believe worked. Wall Street Journal Available at: https://www.wsj.com/articles/how-the-fda-approved-a-300-000-a-year-drug-its-own-experts-didnt-believe-worked-1495116544.
- Thomas, K. 2018. Why can’t dying patients get the drugs they want? New York Times. Available at: https://www.nytimes.com/2018/03/23/health/right-to-try-drugs-fda.html.
- Unger, E.F. 2016. Agency Scientific Dispute – Appeal Re NDA #206488. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488_summary%20review_Redacted.pdf.